10 results about "Contragestazol" patented technology

This invention provides the application of CTH inhibitors and / or xCT inhibitors in the preparation of drugs for inhibiting mammalian embryo implantation, relating to the field of pharmaceutical technology. This invention verifies the efficacy of cystathionine-γ-lyase (CTH) inhibitors and / or solute carrier family 7 member 11 (xCT) inhibitors in inhibiting mammalian embryo implantation. The results show that xCT inhibitors and / or CTH inhibitors can significantly inhibit the proliferation of luteinized granulosa cells and progesterone secretion in mouse models. Furthermore, in vivo injection of xCT inhibitors and / or CTH inhibitors into mouse models not only significantly inhibits ovulation and the maturation rate of released oocytes, but also significantly reduces the formation of functional corpus luteum and embryo implantation. Therefore, this application provides new ideas and methods for the development of contraceptive drugs.

The application relates to the technical field of animal models, in particular to a modeling method and an evaluation method of an animal menstrual dysmenorrhea model and application, wherein the animal with removed ovaries is injected with estrogen, progesterone and oxytocin, the pharmacological injection of progesterone can reduce the harm and mortality rate of the animal caused by the implantation and removal of a progesterone release body in the prior art, the surgical stress of the animal is reduced, the injection time of the progesterone in the application is 7-9 days, and the animal menstrual dysmenorrhea model is obtained after the progesterone is withdrawn for 16 hours; after evaluation by the evaluation method, compared with the non-menstrual process of the dysmenorrhea model in the prior art, the animal menstrual dysmenorrhea model can better simulate the pathophysiological process of human dysmenorrhea, promote the development of clinical treatment, and effectively help patients to relieve pain.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

Embodiments of the invention comprise a test strip configured to detect one or more metabolites of progesterone in urine, and optionally further detect one or more additional metabolites or hormones in urine within the same test strip. Embodiments of the invention are methods of utilizing such a test strip in association with avoidance of pregnancy, detection of menopause, and in association with fertility planning purposes. Embodiments of the invention are associated with the incorporation of a test strip within a testing kit, optionally further comprising a digital reader.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.

The invention discloses a method for measuring the content of progesterone and testosterone in animal waste. The method comprises the following steps: extracting fresh animal excrement by adopting an ethyl acetate-methyl tert-butyl ether solution, carrying out liquid nitrogen blowing and drying on the extracted animal excrement, adding methanol for dissolving, adding water, and uniformly mixing, so as to obtain a sample extracting solution; carrying out enrichment purification treatment on the sample extracting solution by adopting a combined column strategy of a C18 SPE column and an amino SPE column to obtain a solution to be detected; and detecting the contents of the testosterone and the progesterone in the liquid to be detected by adopting an LC-MS method to obtain the contents of the progesterone and the testosterone in the animal waste. According to the method disclosed by the invention, the solid-phase extraction columns are combined for use, so that effective enrichment and purification of testosterone and progesterone in the excrement sample can be realized, interference matrixes in the excrement sample are efficiently removed, the requirements of an LC-MS method on accurate detection of testosterone and progesterone are met, the result is accurate and reliable, and the method is suitable for large-scale popularization and application. The method has very important practical significance for mastering the reproductive cycle of animals, preventing and treating diseases or managing breeding.

The invention discloses a system for promoting in-vitro differentiation of chicken oogonial stem cells and forming blastocysts, and belongs to the technical field of stem cell differentiation culture. According to the invention, retinoic acid (RA) and vitamin C (VC) are added on the basis of an oogonial stem cell culture medium to induce cells to start meiosis, and then follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), glial cell-derived neurotrophic factor (GDNF), progesterone (P4) and rosiglitazone are further added on the basis of the culture medium containing RA and VC to promote the recovery of meiosis, so that the effect of promoting meiosis is achieved. A complete system that the chicken oogonial stem cells are differentiated in vitro and form blastocysts is creatively established by inducing formation of secondary oocytes, direct evidence is provided for in-vitro reconstruction of poultry ovum generation, and a technical basis and application prospects are provided for preservation of female germ cells and large-scale production of the chicken oocytes.

The present disclosure describes a method of quantifying analyte levels using gold nanoparticles. The present disclosure also describes a device to quantify analyte levels using gold nanoparticles and image processing of pixels isolated from a single vector. The methods, devices, and systems of the disclosure can be used to quantify analytes such as luteinizing hormone, progesterone, estradiol, or testosterone.

Device (2) and method for determining a value quantifying a risk of relapse of breast cancer for a patient A device for determining a value quantifying a risk of relapse of breast cancer for a patient comprises a data storage (114) adapted to store patient data associating, for each given patient at a least one whole histological slide image and patient clinical data comprising at least a tumor size, a number of positive lymph nodes, a tumor grade, and progesterone receptor (PR) positivity value, a feature extractor (1210, 1220) arranged to receive a whole histological slide image and associated patient clinical data, to derive tumor architecture features comprising a tumor area, an invasive tumor nest density, a tumor density at the invasive front, and an in situ tumor nest density, tumor microenvironment features comprising a border composition of in situ tumor, a variance of healthy gland size, an inflammatory stroma area, and an average nuclei size of stromal cells, and mitosis features comprising a mitotic hotspot count and a mitotic density, and to return a patient feature vector comprising said tumor architecture features, said tumor microenvironment features, said mitosis features, and features derived from said associated patient clinical data, a risk classifier (1230) using a machine learning module which is arranged to receive a patient feature vector as an input and to return a value quantifying a risk of relapse of breast cancer for a patient, said machine learning module having been trained with a dataset of labelled patient feature vectors and being arranged to return a risk value. This device is arranged to receive a set of patient data of a given patient, to provide at least some of said given patient's whole histological slide image and said given patient's clinical data as inputs to the feature extractor, to provide at least some of the resulting patient feature vectors to the risk classifier, and to return a value quantifying a risk of relapse of breast cancer for a patient for said given patient based on the outputs of the risk classifier.